Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yusuke Fujiwara

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Genes, Chromosomes & Cancer|April 18, 2018
Usefulness of BCOR gene mutation as a prognostic factor in acute myeloid leukemia with intermediate cytogenetic prognosisKazuki Terada, Hiroki Yamaguchi, Toshimitsu Ueki, et al.
Haematologica|June 2, 2016
Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutationsTakeshi Ryotokuji, Hiroki Yamaguchi, Toshimitsu Ueki, et al.
Asia-Pacific Journal of Clinical Oncology|May 23, 2022
Safety and efficacy of high-dose cytarabine MEAM therapy and other treatments for auto-peripheral blood stem cell transplantation: A retrospective comparative studyShunsuke Yui, Satoshi Wakita, Yasunobu Nagata, et al.
Blood Advances|October 21, 2018
Prognostic impact of low allelic ratio <i>FLT3-</i>ITD and <i>NPM1</i> mutation in acute myeloid leukemiaMasahiro Sakaguchi, Hiroki Yamaguchi, Yuho Najima, et al.
International Journal of Hematology|August 22, 2019
Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemiaMasahiro Sakaguchi, Hiroki Yamaguchi, Marika Kuboyama, et al.
International Journal of Hematology|April 4, 2022
NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemiaAtsushi Marumo, Satoshi Wakita, Kaoru Morita, et al.
Blood Advances|August 27, 2021
Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemiaSatoshi Wakita, Masahiro Sakaguchi, Iekuni Oh, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Genes, Chromosomes & Cancer|April 18, 2018
Usefulness of BCOR gene mutation as a prognostic factor in acute myeloid leukemia with intermediate cytogenetic prognosisKazuki Terada, Hiroki Yamaguchi, Toshimitsu Ueki, et al.
Haematologica|June 2, 2016
Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutationsTakeshi Ryotokuji, Hiroki Yamaguchi, Toshimitsu Ueki, et al.
Asia-Pacific Journal of Clinical Oncology|May 23, 2022
Safety and efficacy of high-dose cytarabine MEAM therapy and other treatments for auto-peripheral blood stem cell transplantation: A retrospective comparative studyShunsuke Yui, Satoshi Wakita, Yasunobu Nagata, et al.
Blood Advances|October 21, 2018
Prognostic impact of low allelic ratio <i>FLT3-</i>ITD and <i>NPM1</i> mutation in acute myeloid leukemiaMasahiro Sakaguchi, Hiroki Yamaguchi, Yuho Najima, et al.
International Journal of Hematology|August 22, 2019
Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemiaMasahiro Sakaguchi, Hiroki Yamaguchi, Marika Kuboyama, et al.
International Journal of Hematology|April 4, 2022
NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemiaAtsushi Marumo, Satoshi Wakita, Kaoru Morita, et al.
Blood Advances|August 27, 2021
Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemiaSatoshi Wakita, Masahiro Sakaguchi, Iekuni Oh, et al.
Pageof 6